StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $0.66 | $0.62 | -5.94% | 0.0M |
| 05-12 | $0.62 | $0.66 | +5.48% | 0.0M |
| 05-13 | $0.64 | $0.63 | -0.94% | 0.0M |
| 05-14 | $0.68 | $0.65 | -4.07% | 0.0M |
| 05-15 | $0.66 | $0.64 | -3.50% | 0.0M |
No sell-side coverage available for INM.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for INM.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2022 2022-06-30 | Q1 2022 2022-03-31 | Q4 2021 2021-12-31 | Annual 2021 2021-06-30 |
|---|---|---|---|---|
Revenue | $1.37M | $574.68K | $265.09K | $1.90M |
Operating Income | $-18.60M | $-10.73M | $-7.25M | $-10.20M |
Net Income | $-18.60M | $-10.73M | $-7.25M | $-10.20M |
EPS (Diluted) | $-33.17 | $-20.13 | $-14.03 | $-37.96 |
Total Assets | $12.79M | $15.49M | $19.38M | $9.78M |
Total Liabilities | $3.71M | $4.60M | $5.22M | $2.40M |
Cash & Equivalents | $6.18M | $5.90M | $11.28M | $7.36M |
Free Cash Flow OCF − CapEx | $-15.62M | $-11.58M | $-6.22M | $-9.79M |
Shares Outstanding | 650.67K | 14.28M | 14.14M | 322.03K |
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.